Hofseth BioCare ASA

Share Issue/Capital Change • Nov 20, 2025

Hofseth BioCare ASA: LAST DAY OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFFERING

Hofseth BioCare ASA: LAST DAY OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFFERING

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR

INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER

JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE

UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE

SECURITIES DESCRIBED HEREIN.

Reference is made to the stock exchange announcements by Hofseth BioCare ASA

("HBC" or the "Company") on 7 November 2025 regarding the terms of a subsequent

offering of up to 16,666,666 new shares (the "Offer Shares") in the Company (the

"Subsequent Offering") and on 10 November 2025 regarding the start of the

subscription period in the Subsequent Offering. Each Offer Share is offered at a

subscription price of NOK 1.80.

The subscription period for the Subsequent Offering (the "Subscription Period")

will expire today, 20 November 2025 at 16:30 hours (CET). Subscription rights

that are not used to subscribe for Offer Shares before the expiry of the

Subscription Period will have no value and will lapse without compensation to

the holder.

Correctly completed subscription forms must be received by DNB Carnegie, a part

of DNB Bank ASA (the "Settlement Agent") prior to the expiry of the Subscription

Period, or in the case of online subscriptions, be registered prior to the

expiry of the Subscription Period.

For further information on the Subsequent Offering, please refer to the

Company's stock exchange notice dated 7 November 2025, or in the national

prospectus published by the Company on 10 November 2025 in accordance with the

rules in the Norwegian Securities Trading Act chapter 7 (the "Prospectus"). The

Prospectus is available at the websites of the Company

(https://hofsethbiocare.com).

Advokatfirmaet CLP DA is acting as legal counsel to the Company in the

Subsequent Offering.

For further information, please contact:

Jon Olav Ødegård, CEO at HBC

Phone: +47 936 32 966

E-mail: joo@hofsethbiocare.no (mailto:joo@hofsethbiocare.no)

Important information

This announcement is not and does not form a part of any offer to sell, or a

solicitation of an offer to purchase, any securities of the Company. Copies of

this announcement are not being made and may not be distributed or sent into any

jurisdiction in which such distribution would be unlawful or would require

registration or other measures. The securities referred to in this announcement

have not been and will not be registered under the U.S. Securities Act of 1933,

as amended (the "Securities Act"), and accordingly may not be offered or sold in

the United States absent registration or an applicable exemption from the

registration requirements of the Securities Act and in accordance with

applicable U.S. state securities laws. The Company do not intend to register any

part of the Offering in the United States or to conduct a public offering of

securities in the United States. Any sale in the United States of the securities

mentioned in this announcement will be made solely to "qualified institutional

buyers" as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only

directed at qualified investors in that Member State within the meaning of the

Prospectus Regulation, i.e., only to investors who can receive the offer without

an approved prospectus in such EEA Member State. The "Prospectus Regulation"

means Regulation (EU) 2017/1129, as amended (together with any applicable

implementing measures) in any Member State. This communication is only being

distributed to and is only directed at persons in the United Kingdom that are

(i) investment professionals falling within Article 19(5) of the Financial

Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the

"Order") or (ii) high net worth entities, and other persons to whom this

announcement may lawfully be communicated, falling within Article 49(2)(a) to

(d) of the Order (all such persons together being referred to as "relevant

persons").

This communication must not be acted on or relied on by persons who are not

relevant persons. Any investment or investments activity to which this

communication relates is available only for relevant persons and will be engaged

in only with relevant persons. Persons distributing this communication must

satisfy themselves that it is lawful to do so.

The issue, subscription or purchase of shares or other financial instruments in

the Company is subject to specific legal or regulatory restrictions in certain

jurisdictions. The Company does not assume any responsibility in the event there

is a violation by any person of such restrictions. The distribution of this

release may in certain jurisdictions be restricted by law. Persons into whose

possession this release comes should inform themselves about and observe any

such restrictions. Any failure to comply with these restrictions may constitute

a violation of the securities laws of any such jurisdiction.

Matters discussed in this announcement may constitute forward-looking

statements. Forward-looking statements are statements that are not historical

facts and may be identified by words such as "believe", "expect", "anticipate",

"strategy", "intends", "estimate", "will", "may", "continue", "should" and

similar expressions. Any forward-looking statements in this release are based

upon various assumptions, many of which are based, in turn, upon further

assumptions. Such assumptions are inherently subject to significant known and

unknown risks, uncertainties, contingencies and other important factors which

are difficult or impossible to predict. Such risks, uncertainties, contingencies

and other important factors could cause actual events to differ materially from

the expectations expressed or implied in this release by such forward-looking

statements. The Company does not make any guarantee that the assumptions

underlying any forward-looking statements in this announcement are free from

errors nor does it accept any responsibility for the future accuracy of the

opinions expressed in this announcement or any obligation to update or revise

the statements in this announcement to reflect subsequent events. You should not

place undue reliance on any forward-looking statements in this announcement. The

information, opinions and forward-looking statements contained in this

announcement speak only as at its date and are subject to change without notice.

The Company does not undertake any obligation to review, update, confirm, or to

release publicly any revisions to any forward-looking statements to reflect

events that occur or circumstances that arise in relation to the content of this

announcement.

This announcement is made by and, and is the responsibility of, the Company.

This announcement is for information purposes only and is not to be relied upon

in substitution for the exercise of independent judgment. It is not intended as

investment advice and under no circumstances is it to be used or considered as

an offer to sell, or a solicitation of an offer to buy any securities or a

recommendation to buy or sell any securities of the Company. The distribution of

this announcement and other information may be restricted by law in certain

jurisdictions. Persons into whose possession this announcement or such other

information should come are required to inform themselves about and to observe

any such restrictions. This announcement is an advertisement and is not a

prospectus for the purposes of the Prospectus Regulation as implemented in any

Member State.